Cassiopea claims CB results equal to fin - does this check out?
Research/Science 7/25/2020
Cassiopea Clascoterone finasteride hair loss treatment androgenic alopecia Winlevi acne treatment breezula testosterone hair follicles Minoxidil MPB CB fin acne Rogaine male pattern baldness
Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.
View this post in the Community →
Similar Community Posts Join
5 / 30 resultscommunity Cassiopea Announces FDA Submission of New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years
The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.
community CASSIOPEA ANNOUNCES VERY POSITIVE PHASE II TWELVE MONTHS RESULTS FOR BREEZULA® (CLASCOTERONE) IN TREATING ANDROGENETIC ALOPECIA
Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.
community Cassiopea Announces Very Positive Interim Analysis Phase 2 Results for Breezula® (Clascoterone) in Treating Androgenetic Alopecia
Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.
community Cassiopea announces completion of recruitment of Phase II dose ranging trial of Breezula (CB-03-01) for androgenic alopecia
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
community FDA approves Cassiopea's WINLEVI (CB-03-01, 1% formulation) for Acne
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
Related Research
6 / 32 results
research Industry Update: The Latest Developments in the Field of Therapeutic Delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
research Androgens in Women: Role in Androgen-Mediated Cutaneous Disorders
Androgens play a complex role in skin conditions like acne and hair loss in women, and normal blood levels don't always show true androgen status.
research Androgens and Acne: Perspectives on Clascoterone, the First Topical Androgen Receptor Antagonist
Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
research A Summary of In Vitro, Phase I, and Phase II Studies Evaluating the Mechanism of Action, Safety, and Efficacy of Clascoterone (Cortexolone 17a Propionate, CB-03-01) in Androgenetic Alopecia
Clascoterone safely promotes hair growth similar to minoxidil.
research A Phase 1 Study to Investigate the Effects of Cortexolone 17α-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity
Clascoterone is safe for the heart, even at high doses.
research Androgenetic Alopecia: An Update Of Treatment Options
Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.